{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T08:57:34Z","timestamp":1775984254757,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sigmund Freud Privatuniversit\u00e4t Wien"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Med Wochenschr"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>In a\u00a0retrospective study, we analyzed the prevalence of common cardiovascular comorbidities in 310\u00a0patients with chronic myelomonocytic leukemia (CMML), their potential prognostic impact, and potential correlations with laboratory and molecular features. 115 (36%) patients had a\u00a0documented cardiovascular comorbidity. In these patients, coronary heart disease 41\/115 (36%), atrial fibrillation 34\/115 (29%), and hypertension 75\/115 (64%) were documented. None of these conditions had a\u00a0significant impact on survival. Unexpectedly, patients with cardiovascular comorbidity had a\u00a0lower number of circulating blasts and a\u00a0lower prevalence of <jats:italic>EZH2<\/jats:italic> mutations. Moreover, time to transformation was significantly longer in these patients. Cardiovascular comorbidity does not seem to have a\u00a0major impact on prognosis in CMML patients. The unexpected lower transformation rate in these patients needs to be further investigated.<\/jats:p>","DOI":"10.1007\/s10354-022-00982-7","type":"journal-article","created":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T22:02:35Z","timestamp":1669154555000},"page":"27-33","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Significance of cardiovascular comorbidity in patients with chronic myelomonocytic leukemia","Bedeutung der kardiovaskul\u00e4ren Komorbidit\u00e4t bei Patienten mit chronischer myelomonozyt\u00e4rer Leuk\u00e4mie"],"prefix":"10.1007","volume":"173","author":[{"given":"David","family":"Lackner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1921-7034","authenticated-orcid":false,"given":"Klaus","family":"Geissler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,21]]},"reference":[{"issue":"2","key":"982_CR1","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","volume":"51","author":"JM Bennett","year":"1982","unstructured":"Bennett\u00a0JM, Catovsky\u00a0D, Daniel\u00a0MT, et\u00a0al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51(2):189\u201399.","journal-title":"Br J Haematol"},{"issue":"7","key":"982_CR2","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","volume":"100","author":"JW Vardiman","year":"2002","unstructured":"Vardiman\u00a0JW, Harris\u00a0NL, Brunning\u00a0RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292\u2013302.","journal-title":"Blood"},{"issue":"5","key":"982_CR3","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman\u00a0JW, Thiele\u00a0J, Arber\u00a0DA, et\u00a0al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937\u201351.","journal-title":"Blood"},{"issue":"20","key":"982_CR4","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber\u00a0DA, Orazi\u00a0A, Hasserjian\u00a0R, et\u00a0al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"3","key":"982_CR5","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1182\/blood.V99.3.840","volume":"99","author":"F Onida","year":"2002","unstructured":"Onida\u00a0F, Kantarjian\u00a0HM, Smith\u00a0TL, et\u00a0al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a\u00a0retrospective analysis of 213\u00a0patients. Blood. 2002;99(3):840\u20139.","journal-title":"Blood"},{"issue":"7","key":"982_CR6","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/leu.2013.88","volume":"27","author":"MM Patnaik","year":"2013","unstructured":"Patnaik\u00a0MM, Padron\u00a0E, LaBorde\u00a0RR, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia. 2013;27(7):1504\u201310.","journal-title":"Leukemia"},{"issue":"19","key":"982_CR7","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","volume":"31","author":"R Itzykson","year":"2013","unstructured":"Itzykson\u00a0R, Kosmider\u00a0O, Renneville\u00a0A, et\u00a0al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J\u00a0Clin Oncol. 2013;31(19):2428\u201336.","journal-title":"J Clin Oncol"},{"issue":"10","key":"982_CR8","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","volume":"128","author":"C Elena","year":"2016","unstructured":"Elena\u00a0C, Gall\u00ec\u00a0A, Such\u00a0E, et\u00a0al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128(10):1408\u201317.","journal-title":"Blood"},{"issue":"2","key":"982_CR9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/ejh.13647","volume":"107","author":"S Machherndl-Spandl","year":"2021","unstructured":"Machherndl-Spandl\u00a0S, J\u00e4ger\u00a0E, Barna\u00a0A, et al. Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia. Eur J Haematol. 2021;107(2):265\u201374.","journal-title":"Eur J Haematol"},{"issue":"9","key":"982_CR10","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1200\/JCO.1988.6.9.1417","volume":"6","author":"P Fenaux","year":"1988","unstructured":"Fenaux\u00a0P, Beuscart\u00a0R, Lai\u00a0JL, et\u00a0al. Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107\u00a0cases. J\u00a0Clin Oncol. 1988;6(9):1417\u201324.","journal-title":"J Clin Oncol"},{"issue":"2","key":"982_CR11","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1182\/blood-2002-01-0330","volume":"100","author":"U Germing","year":"2002","unstructured":"Germing\u00a0U, Strupp\u00a0C, Aivado\u00a0M, et\u00a0al. New prognostic parameters for chronic myelomonocytic leukemia. Blood. 2002;100(2):731\u20132. author reply 732\u2013733.","journal-title":"Blood"},{"issue":"11","key":"982_CR12","first-page":"766","volume":"4","author":"AM Storniolo","year":"1990","unstructured":"Storniolo\u00a0AM, Moloney\u00a0WC, Rosenthal\u00a0DS, et\u00a0al. Chronic myelomonocytic leukemia. Leukemia. 1990;4(11):766\u201370.","journal-title":"Leukemia"},{"issue":"12","key":"982_CR13","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/j.leukres.2014.09.003","volume":"38","author":"E Schuler","year":"2014","unstructured":"Schuler\u00a0E, Schroeder\u00a0M, Neukirchen\u00a0J, et\u00a0al. Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias. Leuk Res. 2014;38(12):1413\u20139.","journal-title":"Leuk Res"},{"issue":"10","key":"982_CR14","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/S0025-6196(12)61287-7","volume":"64","author":"A Tefferi","year":"1989","unstructured":"Tefferi\u00a0A, Hoagland\u00a0HC, Therneau\u00a0TM, et\u00a0al. Chronic myelomonocytic leukemia: natural history and prognostic determinants. Mayo Clin Proc. 1989;64(10):1246\u201354.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"982_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1365-2141.1988.tb04173.x","volume":"68","author":"A Worsley","year":"1988","unstructured":"Worsley\u00a0A, Oscier\u00a0DG, Stevens\u00a0J, et\u00a0al. Prognostic features of chronic myelomonocytic leukaemia: a\u00a0modified Bournemouth score gives the best prediction of survival. Br J Haematol. 1988;68(1):17\u201321.","journal-title":"Br J Haematol"},{"issue":"3","key":"982_CR16","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3324\/haematol.2010.030957","volume":"96","author":"E Such","year":"2011","unstructured":"Such\u00a0E, Cervera\u00a0J, Costa\u00a0D, et\u00a0al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica. 2011;96(3):375\u201383.","journal-title":"Haematologica"},{"issue":"15","key":"982_CR17","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","volume":"121","author":"E Such","year":"2013","unstructured":"Such\u00a0E, Germing\u00a0U, Malcovati\u00a0L, et\u00a0al. Development and validation of a\u00a0prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013;121(15):3005\u201315.","journal-title":"Blood"},{"issue":"12","key":"982_CR18","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/ajh.23846","volume":"89","author":"EA Wassie","year":"2014","unstructured":"Wassie\u00a0EA, Itzykson\u00a0R, Lasho\u00a0TL, et al. Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a\u00a0Mayo Clinic-French Consortium Study. Am J Hematol. 2014;89(12):1111\u20135.","journal-title":"Am J Hematol"},{"issue":"6","key":"982_CR19","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.1097\/HS9.0000000000000150","volume":"2","author":"R Itzykson","year":"2018","unstructured":"Itzykson\u00a0R, Fenaux\u00a0P, Bowen\u00a0D, et\u00a0al. Diagnosis and treatment of chronic myelomonocytic leukemias in adults: recommendations from the European Hematology Association and the European leukemianet. Hemasphere. 2018;2(6):e150.","journal-title":"Hemasphere"},{"issue":"11","key":"982_CR20","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1038\/leu.2014.125","volume":"28","author":"MM Patnaik","year":"2014","unstructured":"Patnaik\u00a0MM, Itzykson\u00a0R, Lasho\u00a0TL, et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a\u00a0two-center study of 466\u00a0patients. Leukemia. 2014;28(11):2206\u201312.","journal-title":"Leukemia"},{"issue":"7","key":"982_CR21","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.1038\/bcj.2015.53","volume":"5","author":"E Padron","year":"2015","unstructured":"Padron\u00a0E, Garcia-Manero\u00a0G, Patnaik\u00a0MM, et al. An international data set for CMML validates prognostic scoring systems and demonstrates a\u00a0need for novel prognostication strategies. Blood Cancer\u00a0J. 2015;5(7):e333.","journal-title":"Blood Cancer J"},{"issue":"9963","key":"982_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","volume":"385","author":"GBD 2013 Mortality and Causes of Death Collaborators","year":"2015","unstructured":"GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age\u2014sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: a\u00a0systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117\u201371.","journal-title":"Lancet"},{"issue":"17\u201318","key":"982_CR23","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s00508-019-1526-1","volume":"131","author":"K Geissler","year":"2019","unstructured":"Geissler\u00a0K, J\u00e4ger\u00a0E, Barna\u00a0A, et al. The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML): a representative and useful real-life data source for further biomedical research. Wien Klin Wochenschr. 2019;131(17\u201318):410\u20138.","journal-title":"Wien Klin Wochenschr"},{"issue":"7","key":"982_CR24","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/leu.2013.100","volume":"27","author":"R Itzykson","year":"2013","unstructured":"Itzykson\u00a0R, Solary\u00a0E. An evolutionary perspective on chronic myelomonocytic leukemia. Leukemia. 2013;27(7):1441\u201350.","journal-title":"Leukemia"},{"issue":"4","key":"982_CR25","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/ijlh.13212","volume":"42","author":"K Foucar","year":"2020","unstructured":"Foucar\u00a0K, Hsi\u00a0ED, Wang\u00a0SA, et\u00a0al. Concordance among hematopathologists in classifying blasts plus promonocytes: a bone marrow pathology group study. Int J Lab Hem. 2020;42(4):418\u201322.","journal-title":"Int J Lab Hem"},{"issue":"17","key":"982_CR26","doi-asserted-by":"publisher","first-page":"6057","DOI":"10.3390\/ijms21176057","volume":"21","author":"K Geissler","year":"2020","unstructured":"Geissler\u00a0K, J\u00e4ger\u00a0E, Barna\u00a0A, et al. Molecular basis and clinical application of growth-factor-independent in vitro myeloid colony formation in chronic myelomonocytic leukemia. Int J Mol Sci. 2020;21(17):6057.","journal-title":"Int J Mol Sci"},{"issue":"14","key":"982_CR27","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","volume":"119","author":"HC Hasselbalch","year":"2012","unstructured":"Hasselbalch\u00a0HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a\u00a0trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood. 2012;119(14):3219\u201325.","journal-title":"Blood"},{"issue":"1","key":"982_CR28","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1038\/s41467-020-15497-1","volume":"11","author":"S Hamarsheh","year":"2020","unstructured":"Hamarsheh\u00a0S, Osswald\u00a0L, Saller\u00a0BS, et\u00a0al. Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation. Nat Commun. 2020;11(1):1659.","journal-title":"Nat Commun"},{"issue":"26","key":"982_CR29","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal\u00a0S, Fontanillas\u00a0P, Flannick\u00a0J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N\u00a0Engl J Med. 2014;371(26):2488\u201398.","journal-title":"N Engl J Med"},{"issue":"2","key":"982_CR30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","volume":"377","author":"S Jaiswal","year":"2017","unstructured":"Jaiswal\u00a0S, Natarajan\u00a0P, Silver\u00a0AJ, et\u00a0al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N\u00a0Engl J Med. 2017;377(2):111\u201321.","journal-title":"N Engl J Med"},{"issue":"6327","key":"982_CR31","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1126\/science.aag1381","volume":"355","author":"JJ Fuster","year":"2017","unstructured":"Fuster\u00a0JJ, MacLauchlan\u00a0S, Zuriaga\u00a0MA, et\u00a0al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017;355(6327):842\u20137.","journal-title":"Science"},{"key":"982_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx187","author":"S Khozin","year":"2017","unstructured":"Khozin\u00a0S, Blumenthal\u00a0GM, Pazdur\u00a0R. Real-world data for clinical evidence generation in oncology. J Natl Cancer Inst. 2017; https:\/\/doi.org\/10.1093\/jnci\/djx187.","journal-title":"J. Natl. Cancer Inst."}],"container-title":["Wiener Medizinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-022-00982-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10354-022-00982-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-022-00982-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T07:17:00Z","timestamp":1674631020000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10354-022-00982-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,21]]},"references-count":32,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["982"],"URL":"https:\/\/doi.org\/10.1007\/s10354-022-00982-7","relation":{},"ISSN":["0043-5341","1563-258X"],"issn-type":[{"value":"0043-5341","type":"print"},{"value":"1563-258X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,21]]},"assertion":[{"value":"27 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.\u00a0Lackner and K.\u00a0Geissler declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}